Mediators of Inflammation

Mediators of Inflammation / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 1075975 |

Jessica Zahn, Markus Loibl, Christoph Sprecher, Michael Nerlich, Mauro Alini, Sophie Verrier, Marietta Herrmann, "Platelet-Rich Plasma as an Autologous and Proangiogenic Cell Delivery System", Mediators of Inflammation, vol. 2017, Article ID 1075975, 14 pages, 2017.

Platelet-Rich Plasma as an Autologous and Proangiogenic Cell Delivery System

Academic Editor: Michal A. Rahat
Received20 Jan 2017
Accepted20 Jun 2017
Published06 Aug 2017


Angiogenesis is a key factor in early stages of wound healing and is crucial for the repair of vascularized tissues such as the bone. However, supporting timely revascularization of the defect site still presents a clinical challenge. Tissue engineering approaches delivering endothelial cells or prevascularized constructs may overcome this problem. In the current study, we investigated platelet-rich plasma (PRP) gels as autologous, injectable cell delivery systems for prevascularized constructs. PRP was produced from human thrombocyte concentrates. GFP-expressing human umbilical vein endothelial cells (HUVECs) and human bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in PRP gels in different proportions. The formation of cellular networks was assessed over 14 days by time-lapse microscopy, gene expression analysis, and immunohistology. PRP gels presented a favorable environment for the formation of a three-dimensional (3D) cellular network. The formation of these networks was apparent as early as 3 days after seeding. Networks increased in complexity and branching over time but were only stable in HUVEC-MSC cocultures. The high cell viability together with the 3D capillary-like networks observed at early time points suggests that PRP can be used as an autologous and proangiogenic cell delivery system for the repair of vascularized tissues such as the bone.

1. Introduction

Angiogenesis is crucial for healing and regeneration of vascularized tissues such as the bone [1]. In this process, new capillaries sprout from preexisting vessels to support expanding vascular networks. In the case of large musculoskeletal defects, the surrounding tissue is usually damaged, which may pose a problem since an adequate supply of oxygen and nutrients at the injury site is essential for proper healing [2]. To date, this constitutes still a clinical challenge, because on the one hand, the distance which can be reached by angiogenic sprouting is limited, and on the other hand, the ingrowth of new vessels is a slow process with 5 μm/h [3].

Replacement of the damaged tissue might be a suitable option but is often constricted by the availability of transplantable graft material, for example, bone grafts. Cell-based tissue engineering strategies may overcome these problems. However, it has been shown that the ingrowth of vessels into grafts, as well as the repopulation with endothelial cells into grafts, is not rapid enough to ensure a sufficient blood supply of the grafted cells/tissue [46]. In contrast, preformed networks could be linked to existing vessels within 2–4 days [6, 7]. These findings strongly suggest the use of prevascularized constructs [8].

Cell-based prevascularization of tissue-engineered constructs, using endothelial cells [912], endothelial progenitor cells (EPCs) [1315], or microvascular fragments [16], showed promising results, supporting a fast anastomosis to the host vascular system. Interestingly, it has variously been shown that mural cells, such as mesenchymal stem cells (MSCs), or fibroblasts further promote the vascularization process [9, 10, 13, 15].

The culture and expansion of EPCs and endothelial cells, for example, HUVECs, require proangiogenic growth factors. Such recombinant growth factors are expensive and discussed controversially [17]. The supplementation of growth medium with autologous growth factors would be desirable for clinical application. Platelets are part of the blood and contain more than 5000 proteins. About 300 of the contained proteins, especially growth factors and cytokines, are released upon activation [1820]. The release of cytokines, chemokines, and growth factors induces proliferation and activation of the cells that are involved in wound healing such as fibroblasts, neutrophils, monocytes, smooth muscle cells, and MSC [21]. In addition, our previous work has demonstrated that platelet-derived growth factors can be efficiently used as culture supplement for EPCs [15, 22, 23].

In the last two decades, the treatment with platelet-related plasma (PRP), defined as suspended plasma which contains at least 200,000–1,000,000 platelets/μl suspended plasma [24], is upcoming. PRP can be produced by commercial centrifuges and is used for various clinical applications in the field of orthopedics, for example, cartilage repair [25, 26], ligament healing [2729], and tendon healing [3032]. Although PRP provides a spectrum of growth factors released by platelets, there is no common definition of PRP preparations and often PRP products have not been systematically tested in clinical trials [3335], both hindering comparisons between different studies.

Thrombin and/or calcium chloride are commonly used to activate platelets in PRP [36], which provokes the release of biomolecules and cleavage of fibrinogen resulting in the formation of a fibrin gel. Therefore, activated PRP can be used as an autologous hydrogel [3739]. Taking advantage of an autologous system, PRP has been applied for various in vitro and in vivo studies. Due to its high content of growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), and insulin-like growth factor (IGF) [40], PRP has been used for various applications of musculoskeletal regeneration, orthopedics, and the treatment of ischemic diseases [13, 4144]. We have recently demonstrated that PRP gels can be used as a cell delivery system for MSCs [33]. In this study, we showed that PRP sustained viability and promoted proliferation of encapsulated MSCs in a platelet concentration-dependent manner.

Based on promising preliminary data [45], the aim of the present study was to investigate the angiogenic properties of PRP gels and to evaluate whether PRP can be used as an autologous delivery system for prevascularized structures supporting early neovascularization.

2. Methods

2.1. Bone Marrow- (BM-) Derived Mononuclear Cell (MNC) Isolation and Cell Culture

BM aspirates were obtained from vertebra of patients undergoing orthopedic surgery after informed consent and approval by the local ethics committee (EK Regensburg 12-101-0127). Mononucleated cells (MNCs) were isolated from BM aspirates () by density centrifugation with Ficoll (Histopaque®-1077, Sigma). MNCs were seeded in tissue culture flasks at a density of 5 × 104 cells/ cm2 in αMEM (Gibco) containing 10% FBS (Seraplus, Pan) and 5 ng/ml bFGF (R&D Systems). After 4 days in culture, nonadherent hematopoietic cells were removed. Mesenchymal stem cells (MSCs) selected by adherence to cell culture plastic were further expanded with a change of medium every 3 days. Cells were passaged when 80% confluency was reached, detached using 1% trypsin-EDTA and reseeded at a density of 3 × 103 cells/cm2. All MSCs were used from passages 2 to 4.

GFP-expressing HUVEC cells (HUVEC-GFP, Angio-Proteomie) were cultured on coated plates (Speed Coating Solution, PELObiotech) in complete EGM-2 growth medium (Lonza) at a seeding density of 5 × 103 cells/cm2 and subcultured upon 80% confluency. Cells were used in passages 7–9.

2.2. Cell Labeling of MSCs

For live cell imaging, MSCs were labeled with PKH26® Red Fluorescent Cell Linker Kit for General Cell Membrane Labeling (Sigma Aldrich) prior encapsulation in PRP gels. After detaching and counting of cells, the desired amount of cells were pipetted in a new falcon tube, washed with serum-free αMEM and centrifuged at 400 for 5 min. Cells were resuspended in Diluent C (Sigma) and filtered using a 40 μm cell strainer, and dye working solution was added (2 μl PKH26 Red/1 × 106 MSCs) and incubated for 5 min at room temperature. The labeling reaction was stopped by addition of FBS (SeraPlus), and cells were washed three times with medium and the cell count was determined.

2.3. Preparation of PRP

PRP was produced from human leukocyte-depleted thrombocyte concentrates (blood bank, Kantonsspital Graubünden, Chur, Switzerland) obtained by apheresis containing 1000 × 103 platelets/μl and less than 2 leukocytes/μl. In order to reach an approximately 10-fold increased platelet concentration compared to physiological blood concentration (150–300 × 103 platelets/μl), the platelet concentrates were centrifuged at 2000 for 20 min. The resulting pellet was resuspended in half of the original volume of platelet-depleted plasma, resulting in PRP with 2000 × 103 platelets/μl. PRP was homogenized by sonication for 15 min and stored at −20°C until use. PRP samples () were pooled and randomly matched to normalize for any donor-specific influences.

2.4. Encapsulation of Cells in PRP Gels

For the incorporation of cells into PRP gels, PRP aliquots (pool of 3 donors) were thawed. Cells were seeded in PRP gels at a density of 2.5 × 103 cells per μl gel. For time-lapse microscopy, a gel volume of 20 μl was seeded in μ-slides (μ-Slide Angiogenesis, Ibidi); for histology and gene expression analysis, 120 μl gels were prepared in 96-well plates. Monocultures of each cell type and cocultures were performed as follows: 100% MSCs (100 M), 100% HUVECs (100 H), 75% HUVECs–25% MSCs (75 HM), and 50% HUVECs–50% MSCs (50 HM). Cells were resuspended in PRP and gelation induced by addition of human thrombin (Tisseel, Baxter, final concentration 5 U/ml) and incubation at 37°C for 15–30 min. All gels were cultured under static conditions at 37°C and 5% CO2 in EGM-2 growth medium (Lonza) with 5 μM ε-aminocaproic acid (Sigma).

2.5. Microscopy and Image Analysis

The μ-slides with PRP gels were placed in an onstage incubator linked to an EVOS™ FL Auto Cell Imaging System (ThermoFisher Scientific). The cellular network formation capacity of HUVECs and MSCs in different proportions was analyzed using time-lapse microscopy. Regions of interest were defined before starting of the time lapse to allow tracking of individual cells. Pictures were taken every three hours for 14 days and medium changed every two days. At the end of the experiment, gels were imaged using a LSM 510 confocal imaging system, equipped with an argon and a HeNe1 laser, and mounted on an Axiovert200m microscope with ZEN black software (all Zeiss). Gels were imaged using the 10x and 20x objective at 1272 × 1272 and 2028 × 2028 pixel, respectively.

Image analysis of cellular networks was performed as described before [46]. In brief, the PKH26 Red-labeled MSCs (Figure 1(a)) were imaged with the RFP filter and GFP-HUVECs (Figure 1(b)) with the GFP filter (both ThermoFisher Scientific). The combined images of both fluorescences (Figure 1(c)) generated with the EVOS FL Auto Cell Imaging System (ThermoFisher Scientific) were imported in Axiovision Software (version 4.9.1, Zeiss). For quantification of cellular networks, any tubular structures were marked with a polygon area (Figure 1(d)) and the area measured. The image analysis was performed with the KS400 software (Zeiss) and a custom-made macro. An individual threshold was set for the images of the red-labeled MSCs and GFP-HUVECs, and the area of the respective fluorescent dye within the region of interest was calculated.

2.6. Gene Analysis

Two sample gels were taken and pooled at different time points for gene expression analysis: day 0 (d0), day 7 (d7), and day 14 (d14). For RNA extraction, pooled gels were lysed in 1 ml TriReagent (Sigma) and supplemented with 5 μl Polyacryl Carrier (Molecular Research Center) using a TissueLyser (Qiagen) at 25 Hz for 7 min. After centrifugation at 12000 for 10 min at 4°C, 10% bromochloropropane was added and samples were centrifuged at 12000 for 15 min at 4°C for phase separation. The upper, aqueous phase was collected, and RNA was precipitated using cooled 70% ethanol. RNeasy columns (Qiagen) were used for RNA purification according to the manufacturer’s instructions. RNA purity and concentration was measured with the NanoDrop system (Witec GmbH). Samples were stored at −80°C until use.

cDNA was synthesized from 600 ng RNA using TaqMan® Reverse Transcription reagents (Applied Biosystems, Invitrogen) with random hexamer primers. Real-time PCR was performed using 6 ng cDNA and TaqMan Master Mix (Applied Biosystems) using a Quant Studio 6 Flex machine (Applied Biosystems). Genes of interest were detected using TaqMan Gene Expression Assays (Applied Biosystems) for angiopoietin 1 (Hs00181613_m1), CD146/MCAM (Hs00174838), NG-2/CSPG 4 (Hs00426981_m1), connexin 43 (Hs00748445_s1), collagen IV (Hs00266237_m1), platelet-derived growth factor receptor β1 (PDGFRβ1) (Hs00182163_m1), and Tie 2/Tek receptor (Hs00176096). Vascular endothelial growth factor A (VEGF A) was detected using forward primer 5′-GCC CAC TGA GGA GTC CAA CA-3′, reverse primer 5′-TCCTATGTG CTG GCC TTG GT-3′, and probe 5′-CAC CAT GCA GAT TAT GCG GAT CAA ACC T-3′ (Microsynth). As an endogenous control, human 18s (Hs99999901_m1, ThermoFisher Scientific) was used. All samples were measured in duplicates, and data are presented relative to day 0 using the comparative ∆∆CT method.

2.7. Histology

Histological analysis was performed of gels with mono- and cocultures after 14 days of incubation. Gels were washed once with PBS and then placed in cryomolds with cryocompound Tissue Freezing Medium (Jung). After 15 min of incubation, samples were snap frozen in isopentane and stored at −20°C until use.

Snap-frozen samples were cut in 20 μm thick slices. For immunohistology, cuts were fixed in 70% methanol for 15 min, rehydrated in dH2O, and incubated for 30 min in 99.5% methanol with 30% H2O2 to block endogenous peroxidase activity. After blocking for unspecific antibody binding with horse serum (dilution 1 : 20) at room temperature for 60 min, the primary antibodies connexin 43 (ThermoFisher Scientific) and CD146 (abcam) were put onto the slides (final concentration: 5 μg/μl connexin 43; 1 μg/μl CD146) and incubated for 30 min. Controls were incubated with PBS containing 0.1% Tween (PBST). Afterwards, slides were washed three times with PBST and incubated for 60 min with a secondary anti-mouse antibody (Vectastain ABC kit) at a dilution of 1 : 200. Another washing step (3 × PBST) was performed, the ABC complex of the Vectastain ABC Elite kit was applied, and slides were incubated for 30 min. After washing 3 × with PBST, slides were incubated with ImmunPACT DAB in the dark for 4 min, and after several water changes in dH2O, slides were covered with Prolong Gold antifade reagent with DAPI (ThermoFisher Scientific). Slides were stored at room temperature until observation, and pictures were taken using an Axioplan2 microscope equipped with an AxioCamHRc camera and AxioVision software (Zeiss).

2.8. Statistics

All values are shown as mean ± standard error of the mean (SEM). Statistical analysis of data was performed with GraphPad Prism 7 software. Normal distribution of data was proven using the Shapiro-Wilk normality test. Statistical differences between experimental groups were tested by 2-way ANOVA and Tukey’s post hoc test for multiple comparisons.

3. Results

3.1. Shrinkage of PRP Gels with Encapsulated MSCs

Figure 2 shows representative pictures of PRP gels with and without cells taken at different time points during the culture period. PRP gels without cells retained their original shape, while shrinkage occurred in cell-containing gels. After one week, most pronounced shrinkage could be observed in gels with MSCs monocultures, where gels shrinked to nearly half of their original volume. Moreover, gels containing MSC-HUVEC cocultures (50 HM) demonstrated a reduced size, whereas HUVEC-containing gels were not affected. After two weeks, the shrinkage was still ongoing, however, at a slower rate. Again, shrinkage was most pronounced in gels containing the highest concentrations of MSCs, suggesting that this effect was dependent on the number of encapsulated MSCs.

3.2. Stable Cellular Networks Are Present in HUVEC-MSC Cocultures after 14 Days

Cellular organization within PRP gels was observed by time-lapse microscopy (Figure 3). In HUVEC monocultures, the formation of networks was present as early as 3 days after seeding. Branching and complexity of the networks increased until day 10. Afterwards, structures became disorganized. In contrast to HUVEC monocultures, no networks could be detected in MSC monocultures. In both cocultures (75 HM and 50 HM), cellular networks were observed (Figure 3). Cells were well organized in networks already after 3 days. Defined networks could be observed after one week of culture. In contrast to the monocultures, these networks seemed to be stable for 2 weeks. To note, the 3D nature of cellular networks often hindered a high-quality imaging. To address this issue, high-resolution images were taken with a confocal microscope at the end of the study after 14 days (Figure 4). The findings were in line with the observations from time-lapse imaging (Figure 3). However, high magnification images revealed the contribution of MSCs to the networks (Figures 4(e) and 4(f)).

Based on time-lapse pictures, image analysis was performed to investigate further the formation of cellular networks in different culture conditions (Figure 5). First, we measured the relative percentage of green and red fluorescence in the entire image, representing encapsulated HUVECs and MSCs, respectively (Figures 5(a) and 5(b)). A slight trend of increase in measured green fluorescent signal in the entire image was detected in all conditions by day 3 (Figure 5(a)), raising from 28.7 ± 6.9% to 46.9 ± 16.4%, from 28.4 ± 5.2% to 43 ± 3.3%, and from 27.3 ± 7% to 40.9% in 100 H, 75 HM, and 50 HM cultures, respectively (all ). From there on, signals remained at a constant level, or even decreased to baseline levels with 25 ± 6%, 42 ± 7.9%, and 29 ± 3.5% at day 14 for 100 H, 75 HM, and 50 HM cultures, respectively. A similar pattern was observed for the red fluorescence signal, that is, the MSCs (Figure 5(b)). These findings demonstrate that over the course of the experiment, cells were apparent at least in a similar concentration as at day 0, suggesting that PRP offers an appropriate environment for cells over a time of 2 weeks.

Next, we analyzed the efficiency of network formation in the different culture conditions (Figure 5(c)). Results showed that the main parts of networks were built within the first three days in all conditions, with networks covering 56.3 ± 21.3%, 42.4 ± 10.6%, and 45 ± 7% of the entire image area in 100 H, 75 HM, and 50 HM cultures, respectively (all compared to day 0). For 75 HM and 50 HM cocultures, a stable high area of cellular networks which remained constant over time ( compared to day 0 for all time points) was observed with only minimal differences between both culture conditions. While the speed of initial network formation as well as the percentage of formed networks in HUVEC cultures were comparable to cocultures until day 7 ( compared to day 0 for day 3 and day 7), networks significantly decreased after 10 days, revealing similar concentrations as on day 0 (). After 14 days, networks were only observed in the cocultures with MSCs (53.5 ± 8.3% for 75 HM and 41.7 ± 5% for 50 HM, versus 9.8 ± 1% for 100 H), which led to the suggestion that MSCs play a fundamental role in the stabilization processes of newly formed structures.

Finally, we investigated the contribution of HUVECs (Figure 5(d)) or MSCs (Figure 5(e)) to the marked network area. Analysis revealed that most HUVECs were involved in the formation of networks in all conditions with a relative contribution to the networks ranging from 55% to 87% depending on the culture condition and time point. The fast increase of the green signal measured in networks (Figure 5(d)) affirms again the speed of network formation in all conditions. Although cellular networks were less stable in 100 H monocultures, the contribution of HUVECs to the networks in these cultures was higher compared to cocultures reaching statistical significance from day 7 on (day 7: 100 H 80.9 ± 0.2% versus 50 HM 64.2 ± 4.8% (); day 10: 100 H 75.7 ± 4.6% versus 50 HM 55.2 ± 4.6% (); and day 14: 100 H 87 ± 0.9% versus 75 HM 63.4 ± 3.8% () versus 50 HM 62.8 ± 3.3% ()). With 21–34% of the network area covered by red fluorescence signal, MSCs contributed to the networks as well, however, to a lesser extent as HUVECs.

The fluorescence signal detected outside the marked network area (Figures 5(f) and 5(g)) reflects the timely recruitment of cells to the networks at a merely constant total cell number.

3.3. Analysis of Angiogenic Gene Expression in PRP Gels Containing Cellular Networks

All PRP gels were analyzed for the gene expression related to angiogenesis and vascularization at day 7 and day 14 (Figure 6). First, we measured the expression of VEGF (Figure 6(a)). Although VEGF plays an important role in terms of new vessel formation, data shows no upregulation of VEGF gene expression in PRP gels. However, in contrast to HUVEC monocultures, where VEGF expression was downregulated, gene expression remained stable in cocultures (100 H versus 75 HM at day 14) and MSC monocultures. Of note, the lack of upregulation of VEGF might be related to the fact that both the feeding medium EGM-2 and PRP itself contain high levels of VEGF.

Another main growth factor involved in angiogenic processes is angiopoietin 1, which showed a trend of upregulation in all conditions (ranging from a fold change of 4 to 7 in the different culture conditions, ) at day 14 (Figure 6(b)). In line with the efficient formation of cellular networks in cocultures, angiopoietin 1 was specifically upregulated in these cultures at day 7 (75 HM fold change: 4.6 ± 1.7; 50 HM fold change 8.4 ± 4) which was however not statistically significant (). In contrast to these findings, the angiopoietin receptor Tie 2 did not show a similar pattern as angiopoietin 1 (Figure 6(c)). While Tie 2 gene expression was unchanged in most culture conditions, a slight downregulation was detected in cocultures at day 14 ().

Pericytes, which are closely related to MSCs, are involved in the stabilization of newly formed vessels. Therefore, we analyzed the expression of CD146, NG-2, and PDGFRβ1 as putative pericyte markers (Figures 6(d)6(f)). For CD146, gene expression of MSC monocultures revealed a slight upregulation on day 7 (, Figure 6(d)). In contrast, NG-2 gene expression, which was completely absent in HUVEC monocultures, was downregulated in the MSC monoculture and tended to be stable in cocultures (fold change: 100 M 0.1 versus 75 HM 0.9 ± 0.3 and 50 HM 0.6 ± 0.2, all ). Besides the lack of NG-2 expression in HUVEC monocultures, no differences in NG-2 gene regulation were observed at day 14. A trend of upregulation was apparent for PDGFRβ1 at day 14 with large variations between different cell donors (Figure 6(f)). The highest upregulation of PDGFRβ1 was detected in HUVEC monocultures (fold change 23.5 ± 17.2, ).

Apart from growth factors and their receptors, cell-to-cell contacts, as well as basal membrane proteins play an important role in angiogenesis. Connexin 43 is involved in gap junction cell-to-cell-contacts. A tendency for a slight upregulation of connexin 43 was observed in MSC monocultures (Figure 6(g)), whereas no changes were apparent in collagen IV gene expression, a basal membrane protein (Figure 6(h)).

3.4. Immunohistological Analysis of CD146 and Connexin 43

To evaluate specific markers on protein level, immunohistology was performed on cryosections for CD146, a pericyte marker, and connexin 43, a cell-to-cell contact protein (Figure 7). CD146 was detectable in the presence of HUVECs whereas MSCs alone showed similar results than negative controls indicating that MSC alone did not express CD146 at a detectable level in 3D culture. Connexin 43 was only present in mono- or cocultures containing MSCs.

4. Discussion

In the context of musculoskeletal regeneration, for example, bone defects, limitations in the healing process often occur due to an insufficient blood supply at the defect site. Revascularization involves angiogenic sprouting of vessels from the surrounding tissue, which frequently does not occur in an appropriate time, as the ingrowth of vessels is a long-term process [3]. Therefore, prevascularized implants have been suggested as a promising treatment strategy [615]. The aim of this study was to create an autologous cell delivery system for prevascularized constructs within PRP hydrogels.

In the present study, we showed that PRP is indeed a suitable delivery system for HUVECs, MSCs, and cocultures of both. Cells survived for a period over 14 days which is in line with our previous work [33] demonstrating the viability of MSCs encapsulated in PRP gels for one week.

We noticed that, particularly in the presence of MSCs, PRP gels shrinked over time. Upon in vivo implantation, shrinkage of gels and the herewith associated volume loss may be a limitation for the use of PRP as a cell delivery system. However, shrinkage of gels was not directly related to the formation of networks. In fact, cell assembly to tube-like structures occurred as early as 3 days in cell culture, and thereby, this preceded the significant reduction of gel volume observed after 7 days. This indicates that early implantation of prevascularized PRP gels would be desirable. Short in vitro culture periods would also be most convenient for clinical applications. In addition, mesenchyme-driven condensation of soft matrix has been reported as an important step in the formation of organ buds and the regeneration of functional vascularized tissues [47]. Therefore, the observed shrinkage, which in line with findings from Takebe et al. was mainly driven by MSCs, may be considered as natural step in matrix remodeling.

We observed that PRP gels with cocultures of HUVECs and MSCs formed networks as early as 3 days after cell encapsulation, which were still stable after 2 weeks. This fast network formation might be stimulated by the growth factors secreted from PRP gels [33]. Indeed, since cells were resuspended in PRP upon activation with thrombin, they were immediately exposed to the growth factor release.

In agreement with earlier studies [10, 11, 48], cells (HUVECs and MSCs) took advantage of coculturing. In contrast, no stable networks could be detected in HUVEC monocultures. The maturation of new blood vessels requires the recruitment of mural cells (pericytes or smooth muscle cells) [49] to be stable in the long term. Pericytes are found as single cells, distributed at discontinuous intervals along the basal membrane, which they share with endothelial cells [50]. During angiogenesis, pericytes are stimulated for migration and proliferation before they are recruited to new vessels to contribute to stability. Recently, we have investigated the plasticity of MSCs and their ability to differentiate into a pericyte-like phenotype [51]. This study showed that MSCs upregulated the expression of pericyte markers such as NG-2 and CD146 when they are in direct coculture with bone marrow-derived EPCs [51]. Similarly, Goerke and colleagues showed differentiation of MSCs towards a smooth muscle cell phenotype when coincubated with blood derived EPCs [52]. In line with these findings, MSC supplementation has been proven to promote the formation of stable vessels in various in vitro and in vivo studies [9, 10, 13, 15, 23, 53]. For example, our previous work showed that tissue-engineered constructs composed of EPC-MSC cocultures delivered in PU scaffold in the presence of PRP, promoted vascularization upon subcutaneous implantation [15]. Furthermore, we observed that MSCs indeed display a pericyte-like phenotype in these cocultures [23].

Pericytes, best defined based on their in vivo localization, express several surface markers including CD146 [54, 55], NG-2 [56], α-SMA [57], and PDGFRβ1 [58], which is however dependent on their localization [59]. In the present study, we analyzed the gene expression of CD146, NG-2, and PDGFRβ1. Results gave evidence for a differentiation of MSCs into a pericyte-like phenotype as described above. This was particularly obvious by a much higher expression of NG-2 in cocultures in comparison to HUVEC monocultures. Moreover, we detected a general upregulation of PDGFRβ1 in all cultures. The PDGFβ/PDGFRβ pathway is critically important for the expansion of the pericyte population and pericyte migration along growing vessels [60]. Therefore, upregulation of its gene expression in cocultures might reflect the differentiation and recruitment of MSCs towards the vessel-like structures in PRP gels. Strikingly, also HUVEC monocultures showed an upregulation of PDGFRβ gene expression. Although, endothelial cells usually do not express PDGFRβ1 in high quantities and the relevance of this receptor is unclear in resting endothelium, the current literature provides evidence that PDGFRβ is upregulated under circumstances of angiogenesis [6163]. Therefore, we hypothesize that PDGFRβ upregulation in HUVEC cultures might be caused by the formation of tube-like networks and possibly might be a response to the absence of supporting mural cells. Taken together, in the current study, we only detected a relatively mild increase in the expression of pericyte marker missing statistical significance. Since changes in gene expression are generally transient, it is likely that we might have missed certain changes because only two time points were assessed.

Various signaling pathways are involved in angiogenesis, and it would be of most interest to perform a broad screening of factors involved in the proangiogenic functions of PRP. In this first evaluation of PRP gel as a proangiogenic cell delivery system, we however focused on few key players in angiogenesis; future studies will thoroughly investigate the mechanism of tube-like structure formation in PRP gels. One major growth factor is angiopoietin 1 which acts as a survival signal for endothelial cells and further promotes vascular stabilization by facilitating pericyte recruitment [64, 65]. Here, we show a tendency of angiopoietin 1 upregulation, with the highest upregulations in cocultures of HUVECs and MSCs on day 7 and day 14. However, Tie 2, which is constitutively activated by basal angiopoietin 1 expression [66], was not expressed. An explanation might be the general high expression of Tie 2 on surfaces of mature endothelial cells (HUVECs) which could be seen in gene expression in monoculture conditions. In addition, Tie 2 expression may be delayed to angiopoietin 1 and therefore not be seen at the analysis time points.

In respect of angiogenesis, VEGF is another crucial growth factor for inducing new vessel formation. The fact that the applied growth medium EGM-2 as well as PRP itself already contains VEGF might be a reason why we could not find an upregulation of VEGF gene expression. Moreover, previous studies reported comparable findings since it was shown that new vessel formation is not generally associated with changes in VEGF expression [67, 68].

Moreover, we investigated the expression of the specific cell-to-cell contact protein connexin 43 and found that it was expressed in dependence of MSCs, especially on day 14. Connexin 43 is part of gap junctions and expressed on endothelial cells [69]. In addition, it was previously shown that MSCs overexpressing connexin 43 promote neovascularization [70]. Furthermore, Wang et al. proposed that connexin 43 may act as a potential target for improving the therapeutic efficacy of MSC transplantation. In line with that, we found MSC-dependent expression of connexin 43 on both gene and protein levels. Since vascular network structures were only stable in dependence of MSCs, this leads to the hypothesis that connexin 43 expressed on MSCs may contribute to stabilization processes of cellular networks.

In this study, we present for the first time an autologous delivery system for prevascularized constructs. PRP can easily be harvested by drawing blood which may facilitate the next steps to clinical applications. The fact that PRP is more and more used in clinical studies [29, 32, 71] emphasizes its importance in musculoskeletal healing processes. We demonstrate that PRP has a great potential to support neovascularization, which is a major clinical challenge, particularly in the context of bone repair. While the study confirmed PRP as autologous and proangiogenic cell delivery system, the endothelial cell source (HUVECs) used here cannot be obtained autologously. However, at this stage, we focused on the investigation of these proangiongenic properties of PRP; future studies will address the use of autologous cell sources such as peripheral blood or bone marrow-derived EPCs.

Since the current study is an in vitro experiment, it cannot foresee how cellular networks will sustain in an in vivo environment and how cell-to-cell communication and a supposedly fast in vivo degradation of PRP will impact the stability of tubular structures as well as the anastomosis to the host vascular system. In addition, future studies should be conducted to optimize the system for the application in vivo. These studies should address the implantation technique and time point as well as cell seeding densities. Eventually, it will be interesting to test whether a delivery of cells is necessary or if the chemoattractive and proangiogenic properties of PRP themselves may be sufficient to support neovascularization.

5. Conclusion

To our knowledge, this is the first study to report on an autologous cell delivery system for the delivery of prevascularized structures. Our study shows stable formation of cellular networks by combining HUVECs and MSCs in one culture system. The contribution of MSCs, possibly differentiating into a pericyte-like phenotype, may be crucial for the stabilization of cellular networks.

In conclusion, we demonstrate that PRP can be used as an autologous, proangiogenic cell delivery system promoting early neovascularization.


Marietta Herrmann’s current address is IZKF Group Tissue Regeneration in Musculoskeletal Diseases, Orthopedic Center for Musculoskeletal Research, University Würzburg, Germany.

Conflicts of Interest

The authors declare no conflicts of interests.


The authors wish to thank Andri Hassler and Maria Hildebrand for their technical assistance. This work was funded by the AO Foundation, and a PROMOS Fellowship of University Regensburg was awarded to Jessica Zahn. This work was also supported by the German Research Foundation (DFG) within the funding program Open Access Publishing.


  1. R. A. D. Carano and E. H. Filvaroff, “Angiogenesis and bone repair,” Drug Discovery Today, vol. 8, pp. 980–989, 2003. View at: Google Scholar
  2. E. O. Johnson, T. Troupis, and P. N. Soucacos, “Tissue-engineered vascularized bone grafts: basic science and clinical relevance to trauma and reconstructive microsurgery,” Microsurgery, vol. 31, pp. 176–182, 2011. View at: Publisher Site | Google Scholar
  3. M. W. Laschke and M. D. Menger, “Vascularization in tissue engineering: angiogenesis versus inosculation,” European Surgical Research, vol. 48, pp. 85–92, 2012. View at: Publisher Site | Google Scholar
  4. F. A. Auger, L. Gibot, and D. Lacroix, “The pivotal role of vascularization in tissue engineering,” in Annual Review of Biomedical Engineering, M. L. Yarmush, Ed., vol. 15, pp. 177–200, Annual Reviews, Palo Alto, 2013. View at: Publisher Site | Google Scholar
  5. M. W. Laschke, Y. Harder, M. Amon et al., “Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes,” Tissue Engineering, vol. 12, pp. 2093–2104, 2006. View at: Publisher Site | Google Scholar
  6. P. L. Tremblay, V. Hudon, F. Berthod, L. Germain, and F. A. Auger, “Inosculation of tissue-engineered capillaries with the host’s vasculature in a reconstructed skin transplanted on mice,” American Journal of Transplantation, vol. 5, pp. 1002–1010, 2005. View at: Publisher Site | Google Scholar
  7. M. W. Laschke, B. Vollmar, and M. D. Menger, “Inosculation: connecting the life-sustaining pipelines,” Tissue Engineering Part B, Reviews, vol. 15, pp. 455–465, 2009. View at: Publisher Site | Google Scholar
  8. M. W. Laschke and M. D. Menger, “Prevascularization in tissue engineering: current concepts and future directions,” Biotechnology Advances, vol. 34, pp. 112–121, 2016. View at: Publisher Site | Google Scholar
  9. J. Rouwkema, J. de Boer, and C. A. Van Blitterswijk, “Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct,” Tissue Engineering, vol. 12, pp. 2685–2693, 2006. View at: Publisher Site | Google Scholar
  10. O. Tsigkou, I. Pomerantseva, J. A. Spencer et al., “Engineered vascularized bone grafts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 3311–3316, 2010. View at: Publisher Site | Google Scholar
  11. L. L. Ren, D. Y. Ma, B. Liu et al., “Preparation of three-dimensional vascularized MSC cell sheet constructs for tissue regeneration,” BioMed Research International, vol. 2014, Article ID 301279, 10 pages, 2014. View at: Publisher Site | Google Scholar
  12. F. E. Freeman, A. B. Allen, H. Y. Stevens, R. E. Guldberg, and L. M. McNamara, “Effects of in vitro endochondral priming and pre-vascularisation of human MSC cellular aggregates in vivo,” Stem Cell Research & Therapy, vol. 6, p. 218, 2015. View at: Publisher Site | Google Scholar
  13. X. Chen, A. S. Aledia, S. A. Popson, L. Him, C. C. Hughes, and S. C. George, “Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts,” Tissue Engineering Part A, vol. 16, pp. 585–594, 2010. View at: Publisher Site | Google Scholar
  14. H. Pang, X. H. Wu, S. L. Fu et al., “Prevascularisation with endothelial progenitor cells improved restoration of the architectural and functional properties of newly formed bone for bone reconstruction,” International Orthopaedics, vol. 37, pp. 753–759, 2013. View at: Publisher Site | Google Scholar
  15. M. Herrmann, A. Binder, U. Menzel, S. Zeiter, M. Alini, and S. Verrier, “CD34/CD133 enriched bone marrow progenitor cells promote neovascularization of tissue engineered constructs in vivo,” Stem Cell Research, vol. 13, pp. 465–477, 2014. View at: Publisher Site | Google Scholar
  16. F. S. Frueh, T. Spater, N. Lindenblatt et al., “Adipose tissue-derived microvascular fragments improve vascularization, lymphangiogenesis, and integration of dermal skin substitutes,” The Journal of Investigative Dermatology, vol. 137, pp. 217–227, 2017. View at: Google Scholar
  17. E. Groppa, S. Brkic, E. Bovo et al., “VEGF dose regulates vascular stabilization through semaphorin3A and the neuropilin-1(+) monocyte/TGF-1 paracrine axis,” EMBO Molecular Medicine, vol. 7, pp. 1366–1384, 2015. View at: Google Scholar
  18. L. Senzel, D. V. Gnatenko, and W. F. Bahou, “The platelet proteome,” Current Opinion in Hematology, vol. 16, pp. 329–333, 2009. View at: Google Scholar
  19. R. P. Zahedi, U. Lewandrowski, J. Wiesner et al., “Phosphoproteome of resting human platelets,” Journal of Proteome Research, vol. 7, pp. 526–534, 2008. View at: Google Scholar
  20. M. Ferrari, S. Zia, M. Valbonesi et al., “A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac-surgery,” The International Journal of Artificial Organs, vol. 10, pp. 47–50, 1987. View at: Google Scholar
  21. R. M. Thushara, M. Hemshekhar, Basappa, K. Kemparaju, K. S. Rangappa, and K. S. Girish, “Biologicals, platelet apoptosis and human diseases: an outlook,” Critical Reviews in Oncology/Hematology, vol. 93, pp. 149–158, 2015. View at: Publisher Site | Google Scholar
  22. S. Lippross, M. Loibl, S. Hoppe et al., “Platelet released growth factors boost expansion of bone marrow derived CD34(+) and CD133(+) endothelial progenitor cells for autologous grafting,” Platelets, vol. 22, pp. 422–432, 2011. View at: Google Scholar
  23. F. Duttenhoefer, R. Lara de Freitas, T. Meury et al., “3D scaffolds co-seeded with human endothelial progenitor and mesenchymal stem cells: evidence of prevascularisation within 7 days,” European Cells & Materials, vol. 26, pp. 49–64, 2013, discussion -5. View at: Google Scholar
  24. R. E. Marx, “Platelet-rich plasma (PRP): what is PRP and what is not PRP?” Implant Dentistry, vol. 10, pp. 225–228, 2001. View at: Google Scholar
  25. C. Cavallo, G. Filardo, E. Mariani et al., “Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study,” The Journal of Bone and Joint Surgery American, vol. 96, pp. 423–429, 2014. View at: Google Scholar
  26. X. Xie, C. Zhang, and R. S. Tuan, “Biology of platelet-rich plasma and its clinical application in cartilage repair,” Arthritis Research & Therapy, vol. 16, p. 204, 2014. View at: Google Scholar
  27. L. Andriolo, B. Di Matteo, E. Kon, G. Filardo, G. Venieri, and M. Marcacci, “PRP augmentation for ACL reconstruction,” BioMed Research International, vol. 2015, Article ID 371746, 15 pages, 2015. View at: Publisher Site | Google Scholar
  28. H. J. Braun, A. S. Wasterlain, and J. L. Dragoo, “The use of PRP in ligament and meniscal healing,” Sports Medicine and Arthroscopy Review, vol. 21, pp. 206–212, 2013. View at: Publisher Site | Google Scholar
  29. B. Di Matteo, M. Loibl, L. Andriolo et al., “Biologic agents for anterior cruciate ligament healing: a systematic review,” World Journal of Orthopedics, vol. 7, pp. 592–603, 2016. View at: Google Scholar
  30. J. F. Kaux, P. V. Drion, A. Colige et al., “Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats,” Wound Repair and Regeneration, vol. 20, pp. 748–756, 2012. View at: Google Scholar
  31. G. Filardo, E. Kon, B. Di Matteo et al., “Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: results at 4 years,” Blood Transfusion, vol. 12, pp. 533–540, 2014. View at: Publisher Site | Google Scholar
  32. A. Rowden, P. Dominici, J. D'Orazio et al., “Double-blind, randomized, placebo-controlled study evaluating the use of platelet-rich plasma therapy (PRP) for acute ankle sprains in the emergency department,” The Journal of Emergency Medicine, vol. 49, pp. 546–551, 2015. View at: Google Scholar
  33. J. M. Jalowiec, M. D'Este, J. J. Bara et al., “An in vitro investigation of platelet-rich plasma-gel as a cell and growth factor delivery vehicle for tissue engineering,” Tissue Engineering Part C, Methods, vol. 22, pp. 49–58, 2016. View at: Google Scholar
  34. M. Loibl, S. Lang, G. Brockhoff et al., “The effect of leukocyte-reduced platelet-rich plasma on the proliferation of autologous adipose-tissue derived mesenchymal stem cells,” Clinical Hemorheology and Microcirculation, vol. 61, pp. 599–614, 2016. View at: Google Scholar
  35. M. Loibl, S. Lang, A. Hanke et al., “Leukocyte-reduced platelet-rich plasma alters protein expression of adipose tissue-derived mesenchymal stem cells,” Plastic and Reconstructive Surgery, vol. 138, pp. 397–208, 2016. View at: Google Scholar
  36. C. E. Martinez, S. A. Gonzalez, V. Palma, and P. C. Smith, “Platelet-poor and platelet-rich plasma stimulate bone lineage differentiation in periodontal ligament stem cells,” Journal of Periodontology, vol. 87, pp. E18–E26, 2016. View at: Google Scholar
  37. G. Gobbi and M. Vitale, “Platelet-rich plasma preparations for biological therapy: applications and limits,” Operative Techniques in Orthopaedics, vol. 22, pp. 10–15, 2012. View at: Google Scholar
  38. D. M. Dohan Ehrenfest, I. Andia, M. A. Zumstein, C.-Q. Zhang, N. R. Pinto, and T. Bielecki, “Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives,” Muscles, Ligaments and Tendons Journal, vol. 4, pp. 3–9, 2014. View at: Google Scholar
  39. K. Mautner, G. A. Malanga, J. Smith et al., “A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature,” PM & R, vol. 7, pp. S53–S59, 2015. View at: Publisher Site | Google Scholar
  40. A. Lubkowska, B. Dolegowska, and G. Banfi, “Growth factor content in PRP and their applicability in medicine,” Journal of Biological Regulators and Homeostatic Agents, vol. 26, pp. 3S–22S, 2012. View at: Google Scholar
  41. S. G. Boswell, L. V. Schnabel, H. O. Mohammed, E. A. Sundman, T. Minas, and L. A. Fortier, “Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons,” The American Journal of Sports Medicine, vol. 42, pp. 42–49, 2014. View at: Google Scholar
  42. A. D. Mazzocca, M. B. R. McCarthy, D. M. Chowaniec et al., “The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells,” The American Journal of Sports Medicine, vol. 40, pp. 1742–1749, 2012. View at: Google Scholar
  43. E. A. Sundman, B. J. Cole, V. Karas et al., “The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis,” The American Journal of Sports Medicine, vol. 42, pp. 35–41, 2014. View at: Google Scholar
  44. J. Kurita, M. Miyamoto, Y. Ishii et al., “Enhanced vascularization by controlled release of platelet-rich plasma impregnated in biodegradable gelatin hydrogel,” The Annals of Thoracic Surgery, vol. 92, pp. 837–844, 2011, discussion 44. View at: Google Scholar
  45. J. Zahn, M. Herrmann, M. Loibl, M. Alini, and S. Verrier, “Platelet-rich plasma as autologous cell delivery and pro-angiogenic hydrogel for bone tissue engineering,” Bone & Joint Journal, vol. 99-B, Supplement 2, p. 87, 2017. View at: Google Scholar
  46. M. Herrmann, J. J. Bara, C. M. Sprecher et al., “Pericyte plasticity - comparative investigation of the angiogenic and multilineage potential of pericytes from different human tissues,” European Cells & Materials, vol. 31, pp. 236–249, 2016. View at: Google Scholar
  47. T. Takebe, M. Enomura, E. Yoshizawa et al., “Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation,” Cell Stem Cell, vol. 16, pp. 556–565, 2015. View at: Google Scholar
  48. J. L. Ma, F. Yang, S. K. Both et al., “In vitro and in vivo angiogenic capacity of BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures,” Biofabrication, vol. 6, p. 10, 2014. View at: Google Scholar
  49. S. Reginato, R. Gianni-Barrera, and A. Banfi, “Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis,” Biochemical Society Transactions, vol. 39, pp. 1654–1658, 2011. View at: Google Scholar
  50. A. Armulik, G. Genove, and C. Betsholtz, “Pericytes: developmental, physiological, and pathological perspectives, problems, and promises,” Developmental Cell, vol. 21, pp. 193–215, 2011. View at: Google Scholar
  51. M. Loibl, A. Binder, M. Herrmann et al., “Direct cell-cell contact between mesenchymal stem cells and endothelial progenitor cells induces a pericyte-like phenotype in vitro,” BioMed Research International, vol. 2014, Article ID 395781, 10 pages, 2014. View at: Publisher Site | Google Scholar
  52. S. M. Goerke, J. Plaha, S. Hager et al., “Human endothelial progenitor cells induce extracellular signal-regulated kinase-dependent differentiation of mesenchymal stem cells into smooth muscle cells upon cocultivation,” Tissue Engineering Part A, vol. 18, pp. 2395–2405, 2012. View at: Google Scholar
  53. P. Au, J. Tam, D. Fukumura, and R. K. Jain, “Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature,” Blood, vol. 111, pp. 4551–4558, 2008. View at: Google Scholar
  54. Q. Li, Y. Yu, J. Bischoff, J. B. Mulliken, and B. R. Olsen, “Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin,” The Journal of Pathology, vol. 201, pp. 296–302, 2003. View at: Google Scholar
  55. D. T. Covas, R. A. Panepucci, A. M. Fontes et al., “Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146(+) perivascular cells and fibroblasts,” Experimental Hematology, vol. 36, pp. 642–654, 2008. View at: Google Scholar
  56. F. J. Huang, W. K. You, P. Bonaldo, T. N. Seyfried, E. B. Pasquale, and W. B. Stallcup, “Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse,” Developmental Biology, vol. 344, pp. 1035–1046, 2010. View at: Google Scholar
  57. V. Nehls and D. Drenckhahn, “The versatility of microvascular pericytes - from mesenchyme to smooth-muscle,” Histochemistry, vol. 99, pp. 1–12, 1993. View at: Google Scholar
  58. E. A. Winkler, R. D. Bell, and B. V. Zlokovic, “Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling,” Molecular Neurodegeneration, vol. 5, p. 11, 2010. View at: Google Scholar
  59. L. Diaz-Flores, R. Gutierrez, J. F. Madrid et al., “Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche,” Histology and Histopathology, vol. 24, pp. 909–969, 2009. View at: Publisher Site | Google Scholar
  60. A. Armulik, A. Abramsson, and C. Betsholtz, “Endothelial/pericyte interactions,” Circulation Research, vol. 97, pp. 512–523, 2005. View at: Publisher Site | Google Scholar
  61. M. Hermansson, M. Nister, C. Betsholtz, C. H. Heldin, B. Westermark, and K. Funa, “Endothelial-cell hyperplasia in human glioblastoma - coexpression of messenger RNA for platelet-derived growth-factor (PDGF) b-cain and PDGF receptor suggests autocrine growth-stimulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, pp. 7748–7752, 1988. View at: Google Scholar
  62. K. H. Plate, G. Breier, C. L. Farrell, and W. Risau, “Platelet-derived growth factor receptor-beta is induced during tumor-development and up-regulated during tumor progression in endothelial-cells in human gliomas,” Laboratory Investigation, vol. 67, pp. 529–534, 1992. View at: Google Scholar
  63. M. W. von Ballmoos, Z. J. Yang, J. Volzmann, I. Baumgartner, C. Kalka, and S. Di Santo, “Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFR beta axis-mediated angiogenesis,” PLoS One, vol. 5, p. 10, 2010. View at: Google Scholar
  64. T. Hawighorst, M. Skobe, M. Streit et al., “Activation of the Tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth,” The American Journal of Pathology, vol. 160, pp. 1381–1392, 2002. View at: Google Scholar
  65. E. Fagiani and G. Christofori, “Angiopoietins in angiogenesis,” Cancer Letters, vol. 328, pp. 18–26, 2013. View at: Google Scholar
  66. P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis,” Science, vol. 277, pp. 55–60, 1997. View at: Google Scholar
  67. L. E. Benjamin, I. Hemo, and E. Keshet, “A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF,” Development, vol. 125, pp. 1591–1598, 1998. View at: Google Scholar
  68. L. E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet, “Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal,” The Journal of Clinical Investigation, vol. 103, pp. 159–165, 1999. View at: Google Scholar
  69. F. Villars, B. Guillotin, T. Amedee et al., “Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication,” American Journal of Physiology Cell Physiology, vol. 282, pp. C775–C785, 2002. View at: Google Scholar
  70. D. G. Wang, F. X. Zhang, M. L. Chen, H. J. Zhu, B. Yang, and K. J. Cao, “Cx43 in mesenchymal stem cells promotes angiogenesis of the infarcted heart independent of gap junctions,” Molecular Medicine Reports, vol. 9, pp. 1095–1102, 2014. View at: Publisher Site | Google Scholar
  71. M. Loibl, S. Lang, L. M. Dendl et al., “Leukocyte-reduced platelet-rich plasma treatment of basal thumb arthritis: a pilot study,” BioMed Research International, vol. 2016, Article ID 9262909, 6 pages, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Jessica Zahn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.